MAPT and Alzheimer disease: Thus, dozens of studies have been undertaken to evaluate the extent to which antidiabetic treatments could impact brain pathology (Table 2), especially AD features, with the most part of studies targeting potential benefits on amyloid pathology [118,119], cognitive function [120,121,122], tau pathology [123,124], neuroinflammation [125], oxidative stress [126], neurogenesis [127], and synapses [128,129].